State Street Corp Marker Therapeutics, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.28 - $3.12 $52,494 - $584,943	-187,482 Closed	0 $0
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.46 $520 - $920	-2,000 Reduced 1.06%	187,482 $62,000
Q1 2022 May 16, 2022	SELL	$0.37 - $1.0 $2,652 - $7,169	-7,169 Reduced 3.65%	189,482 $83,000
Q3 2021 Nov 15, 2021	BUY	$1.68 - $2.88 $6,552 - $11,232	3,900 Added 2.02%	196,651 $332,000
Q2 2021 Aug 16, 2021	SELL	$1.88 - $3.56 $720,931 - $1.37 Million	-383,474 Reduced 66.55%	192,751 $538,000
Q1 2021 May 17, 2021	BUY	$1.47 - $3.29 $52,362 - $117,193	35,621 Added 6.59%	576,225 $1.29 Million
Q4 2020 Feb 16, 2021	SELL	$1.36 - $1.75 $29,782 - $38,323	-21,899 Reduced 3.89%	540,604 $784,000
Q3 2020 Nov 10, 2020	BUY	$1.5 - $2.2 $49,248 - $72,230	32,832 Added 6.2%	562,503 $844,000
Q2 2020 Aug 14, 2020	SELL	$1.69 - $2.79 $86,200 - $142,306	-51,006 Reduced 8.78%	529,671 $1.1 Million
Q1 2020 May 11, 2020	BUY	$1.59 - $3.35 $923,276 - $1.95 Million	580,677 New	580,677 $1.1 Million

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $287M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.